--- title: "Definium Therapeutics (DFTX) news: offering" url: "https://aibio.space/companies/definium-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "DFTX offering news: Definium launches $500 million offering, then prices 20,588,236 shares at $34.00. Definium Therapeutics, Inc." --- DFTX Definium Therapeutics, Inc. NASDAQ · United States # Definium Therapeutics (DFTX) news DFTX offering news Financings · 2026-06-22 ## [Definium launches $500 million offering, then prices 20,588,236 shares at $34.00](https://aibio.space/news/definium-launches-500-million-offering-then-prices-20-588-236-shares/) Definium sold 20,588,236 common shares at $34.00, or $700,000,024 before discounts, on the same day it reported that its Emerge depression trial met its primary endpoint. The prospectus supplement names eight underwriters, and its underwriting terms name no counsel. ## Latest Definium Therapeutics news 1. 2025-05-27 Listings [Mind Medicine (now Definium Therapeutics) grants new CFO inducement awards](https://aibio.space/news/mind-medicine-now-definium-therapeutics-grants-new-cfo-inducement/) MindMed named Brandi L. Roberts chief financial officer effective June 2, 2025, with inducement awards of an option on 500,000 shares and 125,000 performance share units. The awards sit outside the company's equity plans, and the lead drug's pivotal trials have not yet reported. 2. 2025-04-21 Debt Financing [Mind Medicine (MindMed) Inc. (now Definium Therapeutics, Inc.) refinances with $42.0 million loan](https://aibio.space/news/mind-medicine-mindmed-inc-now-definium-therapeutics-inc-refinances-42/) The company refinanced its K2 HealthVentures term loans with a $42.0 million first tranche, cut the interest rate and gave lenders the right to convert up to $7.0 million into shares. Up to $120.0 million is available in total, but the filing reports only the first tranche as funded. 3. 2025-04-21 Debt Financing [Mind Medicine (now Definium Therapeutics) amends K2 loan to up to $120.0 million](https://aibio.space/news/mind-medicine-now-definium-therapeutics-amends-k2-loan-up-120-0/) The amendment allows up to $120.0 million of term loans, with a $42.0 million first tranche that refinanced existing loans. Interest carries a floor of 10.25%, lenders can convert up to $7.0 million into shares, and the 8-K gives no cash balance or net loss. ## Definium Therapeutics at a glance - **Ticker**: DFTX - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $1.08 billion ### Related companies - [Enveric Biosciences](https://aibio.space/companies/enveric-biosciences/) NASDAQ: ENVB - [IMMUNOTECH LABORATORIES INC](https://aibio.space/companies/immunotech-laboratories/) OTC: IMMB - [Artiva Biotherapeutics](https://aibio.space/companies/artiva-biotherapeutics/) NASDAQ: ARTV - [Therapeutic Solutions International](https://aibio.space/companies/therapeutic-solutions-international/) OTC: TSOI - [TransCode Therapeutics](https://aibio.space/companies/transcode-therapeutics/) NASDAQ: RNAZ - [Burzynski Research Institute](https://aibio.space/companies/burzynski-research-institute/) OTC: BZYR - [Nutra Pharma](https://aibio.space/companies/nutra-pharma/) OTC: NPHC - [ArriVent BioPharma](https://aibio.space/companies/arrivent-biopharma/) NASDAQ: AVBP ### Also on NASDAQ - [Redhill Biopharma](https://aibio.space/companies/redhill-biopharma/) RDHL - [ORGANIGRAM GLOBAL INC.](https://aibio.space/companies/organigram-global/) OGI - [Eikon Therapeutics](https://aibio.space/companies/eikon-therapeutics/) EIKN - [Black Diamond Therapeutics](https://aibio.space/companies/black-diamond-therapeutics/) BDTX - [ASTROTECH](https://aibio.space/companies/astrotech/) ASTC - [AC Immune SA](https://aibio.space/companies/ac-immune/) ACIU ## What Definium Therapeutics does Definium Therapeutics is a late-stage clinical biopharmaceutical company developing product candidates for brain health disorders, drawn from psychedelic and empathogen drug classes. Its lead candidate, DT120 ODT, is a pharmaceutically optimized form of lysergide D-tartrate in development for generalized anxiety disorder (GAD) and major depressive disorder (MDD). After a Phase 2b trial in GAD met its primary endpoint, the FDA granted breakthrough designation to the DT120 program for GAD in March 2024. Its Phase 3 program for GAD consists of two trials, Voyage and Panorama, and a Phase 3 trial in MDD, Ascend, had sites activated in the first quarter of 2026. Its Voyage trial is expected to report Part A topline results in early third quarter 2026. DT402, also referred to as R(-)-MDMA, is being developed for autism spectrum disorder. The company completed a first clinical trial of DT402 in adult healthy volunteers in October 2024 and initiated a Phase 2a trial in autism spectrum disorder in the fourth quarter of 2025. The company says it applies scientific rigor to psychedelics with the goal of developing accessible treatments for brain health disorders. | Product or program | What it is | Stage | |---|---|---| | DT120 ODT | Lysergide D-tartrate for generalized anxiety disorder and major depressive disorder | Phase 3 | | DT402 | R(-)-MDMA for autism spectrum disorder | Phase 2a | Summarised from the company's [10-K filed Feb 26, 2026](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm). ## Definium Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$117.7 million](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/) | [$65.3 million](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/) | | Net income (loss) | [-$183.8 million](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/) | [-$108.7 million](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/) | | Cash from operations | [-$131.6 million](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/) | [-$79.1 million](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/) | | Cash and equivalents | [$257.8 million](https://www.sec.gov/Archives/edgar/data/1813814/000119312526338066/) | [$273.7 million](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/) | | Short-term investments | [$153.8 million](https://www.sec.gov/Archives/edgar/data/1813814/000119312526338066/) | [$0](https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $655.3 million, plus short-term investments of $428.6 million, $1.08 billion in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Definium Therapeutics Has Definium Therapeutics raised money recently? Our latest story on this, dated Jun 22, 2026: "Definium launches $500 million offering, then prices 20,588,236 shares at $34.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/definium-launches-500-million-offering-then-prices-20-588-236-shares/). What is the ticker symbol of Definium Therapeutics? Definium Therapeutics, Inc. trades under the ticker DFTX on NASDAQ. Where is Definium Therapeutics listed? Definium Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:MMQ0; LS:A420P3; LSX:A420P3. What is the SEC CIK of Definium Therapeutics? The SEC Central Index Key (CIK) for Definium Therapeutics, Inc. is 1813814. Its filings are on SEC EDGAR. How many shares does Definium Therapeutics have outstanding? 134,366,950 shares as of 2026-07-30, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Definium Therapeutics listed under? Our directory records Definium Therapeutics, Inc. under United States. What does Definium Therapeutics do? Our directory classifies Definium Therapeutics, Inc. as: Biopharma / pharmaceutical profile checked. This is a directory classification, not a description of the pipeline. What is the ISIN of Definium Therapeutics? The ISIN recorded for Definium Therapeutics, Inc. is CA24477V1058. Does aibio.space cover Definium Therapeutics? aibio.space lists Definium Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Definium Therapeutics incorporated? SEC records list its state or country of incorporation as A1. What does Definium Therapeutics develop? Definium Therapeutics is a late-stage clinical biopharmaceutical company developing product candidates for brain health disorders, drawn from psychedelic and empathogen drug classes. Its lead candidate, DT120 ODT, is a pharmaceutically optimized form of lysergide D-tartrate in development for generalized anxiety disorder (GAD) and major depressive disorder (MDD). What is DT120 ODT from Definium Therapeutics? DT120 ODT: Lysergide D-tartrate for generalized anxiety disorder and major depressive disorder Stage: Phase 3. What is DT402 from Definium Therapeutics? DT402: R(-)-MDMA for autism spectrum disorder Stage: Phase 2a. Is Definium Therapeutics profitable? Definium Therapeutics, Inc. reported a net loss of $183.8 million for the fiscal year ended Dec 31, 2025, and used $131.6 million of cash in operations, per its annual report to the SEC. How much does Definium Therapeutics spend on research and development? $117.7 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Definium Therapeutics Members talk about Definium Therapeutics (DFTX). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Definium Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-06-22 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1813814/000110465926076393/tm2618395-1_424b5.htm) 2. 2025-10-29 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1813814/000110465925103716/tm2529447-2_424b5.htm) 3. 2025-05-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1813814/000110465925052719/tm2516110d1_ex99-1.htm) 4. 2025-04-21 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1813814/000110465925036841/tm2512703d1_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:DFTX on TradingView](https://www.tradingview.com/symbols/NASDAQ-DFTX/). ## SEC filings and registration - **SEC name**: Definium Therapeutics, Inc. - **CIK**: 1813814 - **Industry (SIC)**: Medicinal Chemicals & Botanical Products (2833) - **US tickers**: DFTX (Nasdaq) - **State or country of incorporation**: A1 - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: ONE WORLD TRADE CENTER, NEW YORK, NY, 10007 - **Phone**: 212-220-6633 - **Shares outstanding**: 134,366,950 as of 2026-07-30 (10-Q filed 2026-08-06) - **Former names**: Mind Medicine (MindMed) Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1813814/000110465926107275/tm2625365d1_8k.htm) filed 2026-09-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1813814/000119312526384403/dftx-20260908.htm) filed 2026-09-08 - [8-K](https://www.sec.gov/Archives/edgar/data/1813814/000110465926094528/tm2622948d1_8k.htm) filed 2026-08-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1813814/000119312526338066/dftx-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1813814/000119312526338006/dftx-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1813814/000110465926077354/tm2618395d3_8k.htm) filed 2026-06-24 - [424B5](https://www.sec.gov/Archives/edgar/data/1813814/000110465926077349/tm2618395-2_424b5.htm) filed 2026-06-24 - [424B5](https://www.sec.gov/Archives/edgar/data/1813814/000110465926076393/tm2618395-1_424b5.htm) filed 2026-06-22 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001813814), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Definium Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker DFTX, recorded under United States. The directory classifies it as Biopharma / pharmaceutical profile checked. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Definium Therapeutics, Inc. - **Ticker**: DFTX - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceutical profile checked - **ISIN**: CA24477V1058 - **Other listed symbols**: GETTEX:MMQ0; LS:A420P3; LSX:A420P3 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-DFTX/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/definium-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Definium Therapeutics (DFTX) news: offering", 2026-10-31, https://aibio.space/companies/definium-therapeutics/